Novavax Inc
NASDAQ:NVAX
Novavax Inc
Revenue
Novavax Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novavax Inc
NASDAQ:NVAX
|
Revenue
$682.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
105%
|
CAGR 10-Years
36%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Novavax Inc
Glance View
Nestled at the intersection of innovation and dedication, Novavax Inc. emerged as a pivotal player in the biopharmaceutical landscape. Founded in 1987, the company was initially envisioned to be a biotechnology firm focused on life-saving vaccines, a mission that would increasingly align with global needs. Through diligent research and development, Novavax adopted a recombinant nanoparticle technology platform, enabling the company to develop distinctive vaccines. Using proprietary adjuvants to bolster immune responses, their work is characterized by precision and high efficacy. Novavax’s journey gained substantial momentum during the COVID-19 pandemic, as the urgent demand for vaccines spotlighted their potential. The development of their COVID-19 vaccine candidate, leveraging this cutting-edge technology, became a critical milestone, underscoring their adaptability and competence in addressing modern health challenges. From a business perspective, Novavax crafts its success by guiding innovative vaccine candidates through rigorous stages of clinical trials and regulatory approvals, ultimately leading to revenue generation via licensing agreements and government contracts. They meticulously balance risk and opportunity by targeting a spectrum of infectious diseases, aiming to broaden their product pipeline and thus capture larger market shares. Revenue flows primarily from the sale of these vaccines, which are distributed worldwide, and the company continues to explore partnerships and collaborations to enhance its market reach. Novavax showcases resilience and forward-thinking strategies, underpinned by a commitment to expanding access to essential vaccines globally, thereby meeting both public health needs and corporate growth objectives.
See Also
What is Novavax Inc's Revenue?
Revenue
682.2m
USD
Based on the financial report for Dec 31, 2024, Novavax Inc's Revenue amounts to 682.2m USD.
What is Novavax Inc's Revenue growth rate?
Revenue CAGR 10Y
36%
Over the last year, the Revenue growth was -31%. The average annual Revenue growth rates for Novavax Inc have been -16% over the past three years , 105% over the past five years , and 36% over the past ten years .
You don't have any saved screeners yet